2022 年第 8 期 第 17 卷

米拉贝隆联合坦索罗辛治疗前列腺增生合并膀胱过度活动症患者的效果及安全性分析

Analysis of the efficacy and safety of mirabegron combined with tamsulosin on treating benign prostatic hyperplasia complicated with overactive bladder

作者：秦国东高渝

英文作者：Qin Guodong Gao Yu

单位：重庆市大足区人民医院泌尿外科，重庆402360

英文单位：

关键词：前列腺增生；膀胱过度活动症；米拉贝隆；坦索罗辛

英文关键词：Prostatichyperplasia;Overactivebladder;Mirabegron;Tamsulosinrplasiacomplicatedwithoveractivebladder

• 摘要：

• 目的 分析米拉贝隆联合坦索罗辛治疗前列腺增生（BPH）合并膀胱过度活动症（OAB）患者的效果及安全性。方法 选取2016年1月至2020年1月重庆市大足区人民医院收治的110例BPH合并OAB患者作为研究对象，应用随机数字表法分为对照组和观察组，各55例。对照组予米拉贝隆缓释片口服治疗，观察组在对照组基础上联合盐酸坦索罗辛缓释胶囊口服治疗，2组均治疗4周。比较2组患者治疗前后的国际前列腺症状评分（IPSS）、OAB患者自我评价量表评分（OABSS）、生活质量评分、最大尿流率、储尿期症状及不良反应发生率。结果 治疗4周后，2组IPSS、OABSS评分均低于治疗前、且观察组低于对照组，生活质量评分均高于治疗前、且观察组高于对照组，差异均有统计学意义（均P＜0.05）。2组最大尿流率均高于治疗前，但观察组低于对照组，储尿期排尿次数、夜尿次数、尿急次数均少于治疗前，且观察组均少于对照组［（8.6±1.2）次比（9.8±1.6）次、（1.3±0.5）次比（2.6±1.1）次、（3.6±1.4）次比（4.5±1.7）次］，差异均有统计学意义（均P＜0.05）。2组不良反应发生率比较差异无统计学意义（P＞0.05）。结论 米拉贝隆联合坦索罗辛能够有效安全地缓解BPH合并OAB患者的临床症状，改善患者的生活质量。

• Objective To analyze the efficacy and safety of mirabegron combined with tamsulosin on treating benign prostatic hyperplasia (BPH) complicated with overactive bladder (OAB). Methods From January 2016 to January 2020, 110 patients with BPH complicated with OAB admitted to the People′s Hospital of Dazu, Chongqing were selected. Patients were divided into control group and observation group according to random number table method, with 55 cases in each group. The control group was given mirabegron sustained-release tablets orally, and the observation group was given tamsulosin hydrochloride sustained-release capsules orally. Both groups were treated for 4 weeks. The international prostate symptom score (IPSS), OBA symptom scale (OABSS) score, quality of life (QOL) score, maximum urinary flow rate, urine storage symptoms before and after treatment and incidence of adverse reactions were compared between the two groups. Results Four weeks after treatment, IPSS and OABSS scores in both groups were lower than those before treatment, and the scores in the observation group were lower than those in the control group; QOL scores in both groups were higher than those before treatment and the score in the observation group was higher than that in the control group (all P<0.05). The maximum urinary flow rates in both groups were higher than those before treatment but the maximum urinary flow rate in the observation group was lower than that in the control group; times of urination, nocturia and urgency during urine storage in both groups were less than those before treatment, and those in the observation group were less than those in the control group［（8.6±1.2）times vs （9.8±1.6）times,（1.3±0.5）times vs （2.6±1.1）times,（3.6±1.4）times vs （4.5±1.7）times］(all P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion Mirabegron combined with tamsulosin can effectively and safely relieve the symptoms of patients with BPH complicated with OAB, and can improve the quality of life of patients.